Wall Street is positive on Nektar Therapeutics (NKTR). On average, analysts give Nektar Therapeutics a Hold rating. The average price target is $2.75, which means analysts expect the stock to gain by 304.41% over the next twelve months.
That average ranking earns Nektar Therapeutics an Analyst Rating of 3, which is better than 3% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NKTR a Hold today. Find out what this means to you and get the rest of the rankings on NKTR!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Nektar Therapeutics Stock Today?
Nektar Therapeutics (NKTR) stock is flat 0.54% while the S&P 500 has risen 0.82% as of 2:30 PM on Wednesday, Feb 7. NKTR is unchanged $0.00 from the previous closing price of $0.68 on volume of 848,347 shares. Over the past year the S&P 500 is higher by 19.96% while NKTR is down -78.41%. NKTR lost -$1.55 per share the over the last 12 months.
Click Here to get the full Stock Report for Nektar Therapeutics stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
